Incidence of the secondary outcome was 23% in COVID-19 patients with high IL-6 levels (above the median of 20.77 pg/ml) vs. 5% in patients with low IL-6 levels (log-rank p = 0.002, HR 4.62 [95%CI, 1.55–13.73], p = 0.006). Here, IL6 is linked to COVID-19.